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Background and purpose: Drug-induced prolongation of the QT interval can lead to torsade de pointes, a life-threatening
ventricular arrhythmia. Finding appropriate assays from among the plethora of options available to predict reliably this serious
adverse effect in humans remains a challenging issue for the discovery and development of drugs. The purpose of the present
study was to develop and verify a reliable and relatively simple approach for assessing, during preclinical development, the
propensity of drugs to prolong the QT interval in humans.
Experimental approach: Sixteen marketed drugs from various pharmacological classes with a known incidence—or lack
thereof—of QT prolongation in humans were examined in hERG (human ether a-go-go-related gene) patch-clamp assay and
an anaesthetized guinea-pig assay for QT prolongation using specific protocols. Drug concentrations in perfusates from hERG
assays and plasma samples from guinea-pigs were determined using liquid chromatography-mass spectrometry.
Key results: Various pharmacological agents that inhibit hERG currents prolong the QT interval in anaesthetized guinea-pigs in
a manner similar to that seen in humans and at comparable drug exposures. Several compounds not associated with QT
prolongation in humans failed to prolong the QT interval in this model.
Conclusions and implications: Analysis of hERG inhibitory potency in conjunction with drug exposures and QT interval
measurements in anaesthetized guinea-pigs can reliably predict, during preclinical drug development, the risk of human QT
prolongation. A strategy is proposed for mitigating the risk of QT prolongation of new chemical entities during early lead
optimization.
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Keywords: drug development; drug-induced QT prolongation; patch clamping; surface ECG (electrocardiogram); TdP
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Introduction
Drug-induced QT prolongation leading to serious ventricular
arrhythmias, such as torsade de pointes (TdP), poses a major
safety consideration for the development and use of new
drug candidates (Crumb and Cavero, 1999). TdP is a unique
form of polymorphic ventricular tachycardia that may result
in a worsening of the patient’s cardiac condition and/or
sudden death. The incidence of TdP with cardiac
pro-arrhythmic drugs is 1–8%, but the incidence with
non-cardiac drugs is considerably lower, approximately
1:10000–1:100000 (Darpo, 2001). TdP is typically not seen
in clinical trials because of its infrequent occurrence. The
mechanism of TdP remains unclear and this uncertainty
makes it difficult to predict it in the early stages of drug
development. However, TdP is always associated with
prolongation of the QT interval of the surface ECG.
Consequently, the presence of a prolonged QT interval has
become a surrogate marker for the possible development of
TdP. Thus, any evidence indicating a QT prolongation by a
new drug is a significant concern in drug development,
as it raises the risk of TdP. QT prolongation issues have
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clinical development of candidate compounds has been
halted as a result of QT prolongation and marketed drugs
have been withdrawn due to a small number of TdP
incidents in humans. Some notable examples include
cisapride, grepafloxicin and terfenadine. Because of this
significant safety issue, regulatory agencies including the
Food and Drug Administration (FDA), the Committee for
Proprietary Medicinal Products (CPMP) and the Interna-
tional Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use
(ICH) have increasingly required pharmaceutical companies
to take serious measures to minimize the risk of drug-
induced TdP (Committee for Proprietary Medicinal Products,
1997; ICH S7A, B; ICH E14).
To protect patients and address the concerns of regulatory
agencies, pharmaceutical companies have employed a
number of preclinical models to evaluate the likelihood of
a compound prolonging the QT interval. Clearly, no single
assay is sufficient to predict the risk of TdP in humans. This
concept is also reflected in the final preclinical guidelines
(ICH S7A and S7B, http://www.ich.org), where both an in
vitro IKr (rapidly activating delayed rectifier potassium
current) (hERG (human ether a-go-go-related gene)) assay
and an in vivo QT assay are recommended to assess a
candidate’s QT prolongation risk. Among the in vitro hERG
assays, functional hERG testing using conventional patch-
clamp electrophysiology is still the most relevant methodology
and remains the gold standard. The telemetered dog and
monkey in vivo models are frequently used for ECG
investigations (Hammond et al., 2001). However, these
assays are often delayed until the late stage of preclinical
development, due to cost and resource constraints. Ideally,
potential QT prolongation issues need to be identified earlier
in drug development to guide structure–activity relationship
to minimize the risk of QT prolongation in new chemical
entities. Thus, there is a critical need for a reliable approach
for accurately and expeditiously predicting the QT prolonga-
tion liability of many compounds during the early stage of
drug development using a less expensive, but predictive,
alternative to the dog or monkey. Among small species, the
guinea-pig, unlike rat and mouse, has a cardiac action
potential and ECG that are similar to humans, and thus
represents a practical, small animal model for assessing QT
interval prolongation early in the drug development process.
This species is also listed as a suitable model for QT
assessment in the ICH S7B guidelines.
Thus, to predict potential QT issues preclinically, we set
out to develop a strategy of using a guinea-pig QT model in
combination with a hERG functional assay, which we
describe herein. This strategy stems from a systematic
examination of the relationships between the potency of
hERG inhibition in conjunction with drug exposures, the
change of QT interval in a guinea-pig model and QT
prolongation/TdP in humans for a variety of therapeutic
agents. Sixteen marketed drugs were examined in the hERG
electrophysiology and anaesthetized guinea-pig QT measure-
ment assays, protocols for which were optimized to yield
consistent, robust data with ease of use. Eight drugs that
have been associated with QT prolongation and TdP
incidents in humans, three drugs that caused QT prolonga-
tion without TdP reported in humans and five drugs that had
no association with QT prolongation and TdP in humans
were included.
Methods
Selection of drugs
Sixteen marketed drugs were selected to cover a wide range
of cardiovascular and non-cardiovascular therapeutic classes,
including antiarrythmics, a gastrointestinal prokinetic, anti-
histamines, an anti-oestrogen, antibiotics, antipsychotics,
antithrombotics and angiotensin-converting enzyme inhibi-
tors. As shown in Table 1, these drugs were divided into three
groups based on their QT prolongation effects and the
numbers of TdP incidents in humans. Group A contained
eight drugs that induce QT prolongation with TdP incidents
reported. The three drugs in group B cause QT prolongation
but have not been reported to cause TdP. Five group C drugs
do not cause QT prolongation or TdP incidents. Commercial
availability was also considered for the selection of drugs.
The source of each drug is listed in Supplementary Table 1.
Medline searches were performed to identify the QTeffects
and TdP incidents for the drugs used in this study. The
majority of Cmax (maximum plasma concentration) values
and ranges for protein binding were found in Goodman and
Gilman’s The Pharmacological Basis of Therapeutics, 11th
Edition (Hardman and Limbird, 2006a,b). Otherwise, they
were found in individual publications indicated in Table 1.
The highest Cmax values and the lowest values of protein
binding were chosen when more than two values were
available. Maximum free drug concentration (free Cmax) was
calculated using the following equation:
FreeCmax ¼ TotalCmax ð1   proteinboundfractionÞ
where the total Cmax was the peak total plasma concentra-
tion and the protein-bound fraction is the proportion of
compound bound to plasma proteins. These plasma levels
are summarized in Table 1.
Cell preparation and voltage-clamp recordings of hERG currents
The hERG potassium channels were stably expressed in the
Chinese hamster ovary (CHO)-K1 cells. The CHO-K1 cells
were maintained in cell media that contained 90% Iscove’s
modified Dulbecco’s medium, 10% foetal bovine serum, 1%
HT supplement, 1% non-essential amino acid (NEAA),
penicillin G sodium 100UmL
 1, streptomycin sulphate
100mgmL
 1 and geneticin 500mgmL
 1. Confluent cells in
flasks were rinsed once with PBS prior to passage. The flasks
were incubated with Versene (EDTA) 1:5000 for 5min at
371C to detach the cells from the flasks. Cells used in
electrophysiology experiments were plated on glass cover
slips 24–48h prior to use.
hERG current recordings were performed using the whole-
cell patch clamp configuration with an AxonMultiClamp
700A amplifier (Axon Instruments, Union City, CA, USA).
Voltage clamp protocols were controlled using pClamp9
(Axon Instruments) acquisition and analysis software as
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stable for up to 45min, and were recorded in control
condition and during the application of the drugs at
different concentrations (n¼4–8 cells for each concentra-
tion). Borosilicate glass patch pipettes were pulled to obtain a
tip resistance of 2–4MO when filled with (mM): KCl 126,
MgSO4 2, CaCl2 0.5, EGTA 5, Mg-ATP 4 and HEPES 25 (pH
7.3). External bath solution consisted of (mM) NaCl 150,
CaCl2 1.8, KCl 4, MgCl2 1, glucose 5 and HEPES 10 (pH 7.4).
The temperature was controlled at 25±0.51C for all experi-
ments using a temperature controller (SHM-6 Multi-Line
Solution Heater) from Warner Instruments (Hamden, CT, USA).
Sotalol, aspirin and amoxicillin were dissolved directly in
the external bath solution to the desired concentrations. All
other drugs were prepared as either a 10 or 100mM stock
solution in dimethylsulphoxide depending on the solubility
limitations and stored at  201C. On the day of experiments,
the stock solution was diluted to the desired concentrations
with bath solution. The final concentration of dimethyl-
sulphoxide in bath solution was 0.1%.
The inhibition of hERG is determined by measuring the
peak amplitude of the tail currents at  40mV before and
after compound application. The half-maximal inhibitory
concentration (IC50) is determined from a curve fit of Hill
equation to the data points:
Y ¼ð 100% ½drug 
nÞ=ð½IC50 
n þ½ drug 
nÞ
where Y is the percent inhibition and n is a coefficient that
determines the slope of the curve.
Animal use and care
All animal procedures in this study were approved by
the GlaxoSmithKline Institutional Animal Care and Use
Committee according to IACUC protocol 593.03. The
guinea-pigs (Charles River, Raleigh, NC, USA) arrived at the
animal service department at least 1 week before the study.
The guinea-pigs were housed in fibreglass cages with food
and water available ad libitum. They were fasted overnight
before the study procedure.
Experimental procedures and recordings of ECG, blood pressure
and heart rate in guinea-pigs
Male Hartley guinea-pigs weighing 450–550g were fasted
18h prior to experimental procedures. The guinea-pigs were
anaesthetized using an intraperitoneal injection of Inactin
(thiobutabarbital sodium salt) 100–120mgkg
 1 and ur-
ethane 1.2gkg
 1. A tracheotomy was performed and the
guinea-pigs were mechanically ventilated (Harvard Apparatus,
Holliston, MA, USA). Tidal volumes were set at 3mL with an
initial ventilation rate of 40–42 strokes per minute and
supplemental oxygen was added. Final ventilation settings
were determined using expired CO2 measurements obtained
from a micro-capnograph (Columbus Instruments, Colum-
bus, OH, USA). Oxygen saturation values were monitored
using a pulse oximeter (Surgivet, Waukesha, WI, USA). The
animal was placed on a heat pad with circulating water at a
temperature of 37–391C. The jugular vein and the carotid
artery were cannulated for drug administration and blood
pressure monitoring, respectively. ECG pin electrodes were
positioned for the standard limb lead and chest lead
configuration. ECG signals were measured from lead II or
V4 lead depending on the integrity of the signal response.
The carotid arterial catheter through a pressure transducer
and ECG cable signals were relayed to a Gould Physiograph
with outputs to a data acquisition system (Ponemah, St Paul,
MN, USA). The blood pressure and ECG were sampled at
Table 1 Published data regarding QT prolongation (LQT) and TdP incidence, maximal plasma concentrations and protein binding in human clinical
use
Incidence Human total
plasma Cmax (mM)
Protein
binding (%)
Reference
Group A
Amiodarone LQT, TdP 3.67 96 Hardman and Limbird (2006a)
Cisapride LQT, TdP 0.13 97.5 Meuldermans et al. (1988); Hardman and Limbird (2006a)
Droperidol LQT, TdP 4.098 90 Fischler et al. (1986)
Haloperidol LQT, TdP 0.106 90 Hardman and Limbird (2006a)
Quinidine LQT, TdP 12 84 Hardman and Limbird (2006a)
D,L-Sotalol LQT, TdP 18.4 0 Hardman and Limbird (2006b)
Sparfloxacin LQT, TdP 9.68 37 Shimada et al. (1993); Morganroth et al. (1999)
Terfenadine LQT, TdP 0.12 97 Monahan et al. (1990); Gonza ´lez and Estes (1998)
Group B
Moxifloxacin LQT 8.68 37 Hardman and Limbird (2006a)
Tamoxifen LQT 0.493 498 Hardman and Limbird (2006a)
Ziprasidone LQT 0.228 499.8 Aweeka et al. (2000); Miceli et al. (2000)
Group C
Amoxicillin None 158.7 18 Hardman and Limbird (2006a)
Aspirin None 110.8 80 Hardman and Limbird (2006c)
Captopril None 3.61 25 Song and White (2002)
Propranolol None
a 0.22 85 Hardman and Limbird (2006a)
Verapamil None 0.55 88 Hardman and Limbird (2006a)
Abbreviation: TdP, torsade de pointes.
aCase report of LQT during overdose.
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were obtained from the ECG channel.
All animals were allowed to stabilize for a 40- to 50-min
period after being instrumented prior to the start of data
collection. Data were collected over a 5-min control period
before drug administration. A vehicle was used to dissolve
the compound initially. Normal physiological saline was
then added to reach the desired concentration for the 1mL
infusion volume. Guinea-pigs received a single dose of
compound or vehicle at a time. To minimize indirect
haemodynamic effects, all animals within each dose group
were given the same infusion volume. All compounds were
infused in all animals at a rate of 1mL over a 10-min period
for each dose given. Data were recorded for 30min
post-infusion. Each drug (or an equal volume of vehicle)
was administered intravenously at the doses shown in
Supplementary Table 1 to five animals per dose, infused
over 10min. After infusion, the animals were monitored
for 30min to assess compound effects. Blood samples
(0.4mL) for determination of drug concentrations were
collected 1 and 31min post-infusion. For each vehicle type,
five control animals were infused with equal volumes of
vehicle following an identical protocol to the drug-treated
groups.
The QT interval is corrected for heart rate changes (QTc) by
using Bazett’s formula:
QTc ¼ð QTintervalinmillisecondsÞ=ðRRintervalinsecondsÞ
1=2
where QTc represents the QT interval corrected for heart rate,
QT represents the interval from the beginning of the Q wave
(onset of ventricular depolarization) through the end of the
T wave (completion of ventricular repolarization) and the
R–R interval is the time between two consecutive heart beats
and is the inverse of the heart rate.
All parameters were averaged on a beat-to-beat basis every
10s and reported out every 30s to a data table. The baseline
values of mean arterial blood pressure, heart rate or QTc
interval consisted of a 5min average of measurements before
drug administration.
For each animal, the post-infusion QTc measurements (60
measurements recorded over 30min) are summarized in the
single number ‘baseline-corrected QTc’, which we defined as
the percent change in mean QTc from baseline (pre-infusion)
to post-infusion.
Doses and vehicles
For each dose of a given drug or vehicle, a separate group of
animals (n¼5) was used; thus, each animal received only a
single treatment of either drug or vehicle. All doses of all
compounds or vehicles were infused intravenously at a rate
of 0.1mL min
 1 over a 10-min period (total volume¼1mL).
Drugs, doses and vehicles are summarized in Supplementary
Table 1. The drug doses were selected to achieve reported
human clinical plasma levels. Our past experience with this
guinea-pig model indicated that a dose of 10mgkg
 1 of a
compound with molecular weight of about 400 resulted in
plasma levels (Cmax) of 2–10mM. In some instances, drug
solubility in an appropriate intravenous formulation
dictated the upper limit of the dose that could be
administered. Physiological saline (0.9%) was used to
dissolve water-soluble drugs. Three other vehicles were
employed to achieve appropriate dosing for the drugs with
poor solubility (see Table 4).
Analyses of drug concentrations in hERG solutions and in plasma
of guinea-pigs
Drug concentrations were determined by atmospheric
pressure ionization-liquid chromatography mass spectro-
metry (LCMS). Three samples of 1mL for each concentration
were taken from the reservoir and perfusate during the
experiments for hERG. The samples were diluted with hERG
buffer and analysed, or extracted with methyl tert-butyl ether
(1mL; Sigma-Aldrich, St Louis, MO, USA) before analysis. After
extraction/dilution, the sample was injected onto the analy-
tical column of an LCMS instrument (Hewlett-Packard Series
1100 Liquid Chromatograph Mass Selective Detector). Drugs
and internal standards were detected as molecular ions
([MþH]
þ) in the positive selected ion-monitoring mode of
the instrumentation. Drug concentration (nanogram or
microgram per millilitre) in the samples was calculated with
a calibration curve constructed from the peak area ratios
(drug peak area/internal standard peak area) using a
weighted linear regression. The concentration of drug in
the sample was determined by interpolation from the
regression line. The average differences between measured
concentrations and expected concentrations were less than
8% (data not shown).
Internal standards of various compounds from this study
(20mL) were added to plasma samples (50–100mL), vortexed
and then precipitated with acetonitrile (Sigma-Aldrich; 1:3 v/v)
or extracted with methyl tert-butyl ether (1mL), centrifuged
at 7280g for 5min, dried down in a TurboVap under
nitrogen and reconstituted in mobile phase prior to analysis.
Statistical considerations
All statistical calculations were carried out using JMP 7.0 or
SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA). For each
compound, we performed ANOVA to compare baseline-
corrected QTc for the low, medium and high doses to vehicle
(compound-matched). Because we were interested in QTc
increases, we performed one-sided comparisons to vehicle.
We used P¼0.05 as our cutoff for determining statistically
significant increases.
Results
Effects of the drugs on hERG
hERG currents were recorded under control conditions and
during the application of the drugs at different concentra-
tions. An example is shown in Figure 1, hERG tail currents
were blocked by verapamil in a concentration-dependent
manner with an IC50 value of 0.94mM.A nI C 50 value was
generated for each drug, except for class C drugs (amoxi-
cillin, aspirin and captopril) where no hERG inhibition was
observed. The percent inhibition of hERG current was taken
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by their solubility. The effects on hERG currents of the drugs
evaluated in this study are summarized in Table 2. The IC50
values for the drugs in all three groups are widely scattered.
All drugs, except sotalol in group A, that induce QT
prolongation and TdP incidence in humans had significant
inhibitory effects on hERG. The IC50 values for group A drugs
ranged from 15nM to 556mM. Most of the drugs in group A
had potent hERG inhibitory effects. The drugs in group B
that induced QT prolongation without TdP incidence
showed significant hERG inhibitory effects as well. In
general, the drugs in group C, which do not prolong QT
and have no TdP reports, demonstrated significantly higher
hERG IC50 values. The hERG IC50 values were not clearly
separated among these three groups although there was a
trend towards a decrease in hERG potency when moving
from group A to group B.
Calculation of safety margins between hERG IC50 and plasma
Cmax of drugs in clinical use in conjunction with QT prolongation
and TdP incidence in humans
In a survey of the literature, Redfern et al. reported that the
margin between the hERG IC50 value and plasma exposure of
the drug might be a valuable parameter for predicting the
risk of QT prolongation and TdP induced by a hERG blocker.
We calculated this margin, termed safety margin (SM), as the
mean of IC50 value divided by the highest quoted value of
the maximal plasma concentration in clinical use. In the
case of terfenadine, the plasma concentration is from a case
report of a drug interaction causing inhibition of cyto-
chrome P450 enzymes; normally, the plasma levels of
terfenadine are very low due to extensive first pass
metabolism through this mechanism (Monahan et al.,
1990). Two SMs were calculated for each drug using the
total plasma concentration and unbound or free plasma
concentration, which we refer to as the total SM (SM-total)
and free SM (SM-free), respectively. As shown in Table 2, the
total SMs for groups A and B were similar, which ranged from
0.07 to 30.2 for group A and from 0.6 to 27 for group B.
Sotalol showed a markedly larger total margin of 30.2. The
free SMs for group A were generally lower than group B
(Figure 2). The free SMs for group A were in the range of 0.7
and 28. All of the free SMs for group B were greater than 30
with values ranging from 42 to 286. In group C, all free SMs
were greater than 300, and the total SMs were larger than 50
with the exception of verapamil, which had smaller free (1.6)
and total (14) SMs. The relationships between the free SMs
for groups A, B and C are shown in Figure 2. Interestingly,
groups B and C had significantly higher free SMs than
group A. Each group differs from its neighbour by approxi-
mately one log unit (that is, 10-fold), which provides
some heuristic support for considering cutoff values of 30
Table 2 Summary of hERG IC50 values and safety margins
hERG IC50
(mM)
Total safety margin
(hERG IC50/
total Cmax)
Free safety margin
(hERG IC50/
free Cmax)
Group A
Amiodarone 0.546 0.15 3.7
Cisapride 0.091 0.7 28
Droperidol 0.307 0.075 0.749
Haloperidol 0.015 0.1 1.4
Quinidine 1.5 0.125 0.78
D,L-Sotalol 556 30.2 30.2
Sparfloxacin 24 2.477 3.757
Terfenadine 0.061 0.5 16.9
Group B
Moxifloxacin 235 27 42
Tamoxifen 0.777 1.58 78.88
Ziprasidone 0.165 0.573 286.45
Group C
Amoxicillin 450000 4315 4384
Aspirin 4100000 4902 44512
Captopril 43000 4831 41382
Propranolol 9.9 49.5 330
Verapamil 0.94 1.6 14.2
Abbreviation: hERG, human ether a-go-go-related gene.
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Figure 1 Effects of verapamil on hERG (human ether a-go-go-
related gene) potassium currents. (a) Stably transfected Chinese
hamster ovary (CHO)-K1 cells were held at  80mV, then stepped to
þ20mV for 400ms followed by a second pulse to  40mV for
400ms to elicit large, slowly deactivating hERG tail currents. This
pulse protocol was repeated every 10sec while the cells were
exposed to verapamil at different concentrations. (b) The percent
inhibition at each dose was calculated (n¼4–8 cells for each
concentration), and the concentration–response curve was then
fitted to a Hill equation as described in the Methods. In this example,
the IC50 for verapamil inhibition of hERG was 0.94mM. The IC50
values for the other drugs evaluated in this study are listed
in Table 2.
Predicting QT prolongation in humans
XY a oet al 1450
British Journal of Pharmacology (2008) 154 1446–1456and 300 to distinguish between the free SMs of the three
groups. These cutoff values are indicated by dashed lines in
Figure 2. In fact, the difference of free SM between groups A
and B was statistically significant (P¼0.0005) (data not
shown).
Effects of drugs on QTc interval in guinea-pigs
Each of the drug doses was administered on a milligram per
kilogram basis by slow intravenous infusion over 10min. For
each animal, baseline-corrected QTc was calculated as the
percent change in mean QTc from baseline (that is, pre-
infusion) to post-infusion (that is, from 10.5 to 40min after
the start of the 10-min infusion period). Examples for a drug
from groups B and C are shown in Figure 3, and the baseline-
corrected QTc results are listed in Table 3.
Group A drugs (agents associated with prolonged QT
interval as well as TdP in humans), which included
amiodorone, cisapride, droperidol, haloperidol, quinidine,
sotalol, sparfloxacin and terfenadine caused significant
(Pp0.05) increases in QTc above vehicle for at least one of
the doses administered (Figure 4). Additionally, clear dose–
response curves were noted for five of the eight group A
drugs. The QTc changes with amiodarone were highly
variable, as were those observed with the low dose of
cisapride; this variability may have contributed to the lack
of a clear dose–response relationship. Because of the marked
bradycardia and resultant hypotension, the maximum dose
of terfenadine was limited to 3mgkg
 1, thus limiting the
potential overall maximum changes. For the highest dose
level of the eight drugs in group A, the mean baseline-
corrected QTc values ranged from 6.9% (amiodarone) to
20.0% (sparfloxacin). The corresponding increases over
vehicle ranged from 5.6% (amiodarone) to 19.6% (sparflox-
acin) (Figure 4).
Group B drugs (agents associated with QTc prolongation,
but not TdP in humans) included moxifloxacin, tamoxifen
and ziprasidone. These agents elicited significant increases in
QTc of a similar magnitude to the group A compounds. For all
three group B drugs, QTc increased significantly above vehicle
at both the second and third doses given. For the highest dose
level of the three drugs in group B, the mean baseline-
corrected QTc values ranged from 8.4% (tamoxifen) to 18.3%
(moxifloxican). The corresponding increases over vehicle
ranged from 6.8% (tamoxifen) to 16.8% (moxifloxican).
Group C drugs (agents not associated with QTc prolonga-
tion or TdP in clinical use) were captopril, verapamil,
propranolol, amoxicillin and aspirin. For the highest dose
level of these five drugs, the mean baseline-corrected QTc
values ranged from  6.0% (captopril) to 3.9% (amoxicillin).
The corresponding changes with vehicle ranged from  7.3%
(captopril) to þ2.4% (amoxicillin). No drugs in group C
showed a significant increase in QTc over vehicle. In fact,
QTc actually dropped below vehicle for captopril and
verapamil. These decreases probably reflect significant
haemodynamic changes and multiple ion channel (that is,
calcium channel inhibition) effects, respectively.
In the past, when using this guinea-pig protocol with these
or similar vehicles, we considered QTc increases of 5% over
vehicle as pharmacologically important safety signals.
Figure 4 shows baseline-corrected QTc, expressed as differ-
ence from vehicle, for every compound and dose. Doses with
a significant (Pp0.05) increase over vehicle are marked with
an asterisk. Every compound in groups A and B showed a
statistically significant increase over vehicle for one or more
doses, but none of the compounds in group C showed a
statistically significant increase over vehicle. Additionally,
every compound in groups A and B but none of the group C
drugs exceeded the 5% risk signal for one or more doses.
No significant heart rate or blood pressure changes
occurred in any of the vehicles used in these studies. The
baseline blood pressures were stable and maintained within
the ranges of 33–47mmHg for all groups, with mean values
of 39±3mmHg. Baselines heart rate ranges were 194–
267b.p.m. (beats per minute) with an overall group mean
of 230±16b.p.m. QTc, heart rate and mean blood pressure
changes for all drugs and vehicles are provided in Supple-
mentary Tables 2–5.
Discussion and conclusions
Numerous reviews and studies have attempted to evaluate
relationships between hERG potency, QTc changes in
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Figure 2 Free safety margins were calculated by dividing the hERG
(human ether a-go-go-related gene) IC50 values (Table 2) by the
therapeutic free Cmax plasma concentrations calculated using the
total Cmax and the protein binding from Table 1. Group A (open
circles, J) contains eight drugs that induce QTc (heart rate
corrected QT interval of the ECG) prolongation with TdP incidents
reported. The three drugs in group B (plus symbols, þ) cause QTc
prolongation but have not been reported to cause TdP. Neither QTc
prolongation nor TdP incidents were found for the five drugs in
group C (multiplication symbols,  ). The dashed horizontal lines
represent free safety margins of 30 and 300.
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(Carlsson, 2001; Hammond et al., 2001; Champeroux et al.,
2005). However, comparisons of data from different sources
and experimental protocols have been difficult. hERG IC50
values for a drug can vary by up to 20-fold (Crumb, 2000;
Kirsch et al., 2004). Often, as drug concentrations in the
hERG perfusate are not analysed, their contribution to
discrepancies in data from different sources is impossible to
ascertain. The QTc data are even harder to compare across
studies due to differences in species and experimental
protocols. The present study is the first effort to correlate
the outcomes of both in vitro functional hERG and in vivo
QTc assays under defined conditions using specific protocols
within the same laboratory for a variety of therapeutic agents
with human data.
All drugs in groups A and B that caused QT prolongation in
humans also showed concentration-dependent and pharma-
cologically relevant hERG inhibition. However, the IC50
values were not clearly separated between groups A and B,
suggesting that a risk of TdP cannot be predicted from hERG
IC50 values alone. The hERG liability may be placed in
context with TdP incidence in humans by calculating an SM
based on the IC50 for inhibition of hERG divided by the
maximal free plasma concentration of drug in clinical
conditions (Webster et al., 2002; Redfern et al., 2003; De
Bruin et al., 2005). In the present study, we demonstrated
that an SM-free of 30 may differentiate between group A and
B drugs (Figure 2), that is, drugs that induce TdP versus drugs
that only cause QT prolongation. A 30-fold SM-free has also
been derived by other groups based on literature surveys and
analyses (Webster et al., 2002; Redfern et al., 2003).
Three group C drugs that do not cause QT prolongation in
humans (aspirin, amoxicillin and captopril) also failed to
potently inhibit hERG (IC50 values above 1000mM) and had
SM-free above 300. These findings suggest that an SM-free of
300 or more may denote a compound devoid of a potential
for causing QTc prolongation. Propranolol has not been
reported to cause QT prolongation in clinical use. However, a
recent report indicated that an overdose of propranolol in a
patient led to QT prolongation (Farhangi and Sansone,
2003). We previously demonstrated that propranolol inhibits
hERG potassium channels with an IC50 of 10mM, which is
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Figure 3 Example of a drug that prolongs the QT interval (moxifloxacin) (a) versus another that does not (amoxicillin) (b). Baseline-corrected
QTc (heart rate corrected QT interval of the ECG) time courses (left panel) and averaged responses (right panel) in each case are depicted. Each
of the drug doses was administered to anaesthetized guinea-pigs on a milligram per kilogram basis by slow intravenous infusion over 10min
(horizontal bars). For each animal, baseline-corrected QTc interval was calculated by comparing the mean QTc interval during baseline (that is,
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the data are summarized in Figure 4.
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British Journal of Pharmacology (2008) 154 1446–1456about 300- to 530-fold higher than its maximum free plasma
concentration at therapeutic doses. Therefore, propranolol is
unlikely to induce QTc prolongation at therapeutic doses
(Yao et al., 2005). In general, the SM-free value of a drug
candidate should exceed 300 to be considered safe from
causing QT prolongation. In our experience, for typical drug
projects in metabolic diseases, a compound that satisfies
SM-free 4300 usually must have a hERG IC50 greater
than 10mM. The free plasma Cmax of the drug at therapeutic
exposures can be obtained from appropriate animal
models of efficacy utilized during the early stages of drug
development.
The guinea-pig is an established small animal model for
cardiac research because its cardiac ion channel profile (with
the exception of ITO) resembles that of humans (Busch et al.,
1994), as does its ECG, with easily identifiable P, QRS and T
waves. During the lead-optimization phase of drug discovery,
drug availability is usually limited and a small, inexpensive
animal model such as the guinea-pig that can provide QTc
prolongation data alongside pharmacokinetic measures is
highly desirable. Both conscious and anaesthetized guinea-
pigs have been used to examine the effects of pro-arrhythmic
drugs on the QT interval or the monophasic action potential
duration in vivo (Lu et al., 1993; Sosunov et al., 1996;
Minematsu et al., 1999). The draft guideline ICH S7B Step 2
Revision (2004) allows an anaesthetized model to be used for
QT measurements, and the Japanese Guidelines for Non-
clinical Studies of Drugs Manual (1995) advises the use of
anaesthetized animals. Data from the Japan Manufacturers’
Table 3 Summary of baseline-corrected QTc and peak plasma levels in
the anaesthetized guinea-pig
Dose (mgkg
 1) Peak plasma level
(mm)(n)
Baseline-corrected
QTc (D%)(n)
Group A
Amiodarone (vehicle 1)
5 6.0±1.4 (4) 8.0±5.1 (5)
10 58.3±9.6 (3) 13.0±5.2 (4)
20 240±52.7 (5) 6.9±3.8 (5)
Cisapride (vehicle 2)
0.1 0.037±0.023 (4) 8.5±3.6 (5)
0.3 0.129±0.032 (4) 6.6±2.4 (5)
1 0.496±0.085 (5) 18.2±1.9 (5)
Droperidol (vehicle 1)
0.03 0.55±0.07 (3) 2.1±3.2 (5)
0.1 0.62±0.05 (5) 6.7±2.3 (5)
0.3 1.21±0.34 (5) 19.1±4.8 (5)
Haloperidol (vehicle 3)
0.01 0.010±0.003 (3) 1.5±0.8 (5)
0.1 0.113±0.012 (4) 4.3±1.2 (5)
1 0.712±0.137 (5) 15.8±3.6 (5)
Quinidine (vehicle 2)
3 6.2±0.08 (3) 8.5±1.5 (5)
10 27.8±8.0 (5) 13.7±2.9 (5)
30 Not determined 15.6±4.9 (4)
Sotalol (vehicle 1)
1 18.2±1.5 (5) 18.1±5.3 (5)
3 41.3±4.8 (4) 10.9±1.8 (5)
10 145.9±16.6 (5) 18.9±6.6 (5)
Sparfloxacin (vehicle 4)
3 23.5±4.2 (3) 6.6±0.9 (5)
10 80.4±9.1 (5) 9.8±1.7 (5)
30 159.4±22.4 (4) 20.0±3.3 (5)
Terfenadine (vehicle 3)
0.3 0.23±0.03 (3) 2.8±0.8 (5)
1 1.28±0.07 (3) 8.0±2.0 (5)
3 3.04±±1.07 (3) 11.7±1.2 (5)
Group B
Moxifloxacin (vehicle 3)
1 2.08±0.28 (4) 0.9±1.7 (5)
5 30.6±7.2 (4) 11.2±3.0 (5)
10 80.5±4.0 (5) 18.3±4.4 (5)
Tamoxifen (vehicle 3)
3 3.8±0.8 (4) 2.2±1.0 (5)
10 10.5±2.1 (5) 10.2±3.9 (5)
30 60.0±20.0 (5) 8.4±1.4 (5)
Ziprasidone (vehicle 1)
0.1 1.1±0.2 (4) 4.9±2.0 (5)
0.3 1.2±0.1 (2) 7.0±1.9 (5)
1 4.0±2.2 (2) 9.1±1.0 (5)
Group C
Amoxicillin (vehicle 3)
3 4.8±0.5 (5) 4.2±2.0 (5)
10 14.6±1.4 (4) 4.4±1.6 (5)
20 30.3±2.5 (5) 3.9±0.3 (5)
Aspirin (vehicle 1)
1 31.1±2.3 (5) 0.5±0.8 (5)
3 74.6±2.1 (5) 1.3±0.6 (5)
10 468±78 (4) 2.5±1.8 (5)
Table 3 Continued
Dose (mgkg
 1) Peak plasma level
(mm)(n)
Baseline-corrected
QTc (D%)(n)
Captopril (vehicle 1)
3 57.8±1.6 (2) 0.0±0.9 (5)
10 142±15 (2)  1.3±1.4 (5)
30 313±112 (2)  6.0±1.9 (4)
Propranolol (vehicle 1)
0.3 0.50±0.03 (3)  1.6±1.2 (5)
1 1.84±0.41 (3) 2.7±1.3 (5)
3 4.65±0.40 (5) 1.1±1.4 (5)
Verapamil (vehicle 1)
0.25 0.48±0.04 (4)  0.9±0.7 (5)
0.5 0.73±0.03 (2)  2.3±1.7 (5)
1 1.97±0.37 (4)  0.4±2.0 (5)
Abbreviation: QTc, heart rate corrected QT interval of the ECG.
Table 4 Effects of vehicles on baseline-corrected QTc in the
anaesthetized guinea pig
Vehicles Composition Baseline-corrected
QTc (D%)(n)
1 0.9% NaCl 1.3±0.8 (5)
2 15% HP-b-cyclodextrin in 25mM
methanesulphonic acid
1.5±0.1 (5)
3 5% DMSO–10% SBE–cyclodextrin in 5mM
methanesulphonic acid
1.6±0.8 (5)
41 0 m g m L
 1 lactic acid in 5% dextrose
in water
0.4±1.2 (5)
Abbreviation: QTc, heart rate corrected QT interval of the ECG.
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British Journal of Pharmacology (2008) 154 1446–1456Association PRODACT Initiative confirmed that the anaes-
thetized dog is a sensitive model for detecting drug-induced
effects on QT interval (Tashibu et al., 2005). QTc prolonga-
tion has been shown in guinea-pigs for terfenadine, cisapride
and sotalol, as it has in humans (Gras and Llenas, 1999; Kii
et al., 2001; Hamlin et al., 2003; Fossa et al., 2004; Testai et al.,
2004; Hauser et al., 2005). Isolated guinea-pig heart prepara-
tions have been used for studying pro-arrhythmic effects and
TdP potential of compounds (Gerhardy et al., 1998).
Certain elements of the specific protocols used in our
hERG and guinea-pig studies are critical to the sensitivity,
precision and accuracy of the readouts, which in turn,
directly impact the correlation analyses. We employed a 400-
ms pulse protocol in our hERG protocol because the duration
is similar to the cardiac action potential. Longer duration
pulse protocols are commonly used to test drug effects
during supramaximal channel activation. Although our
shorter pulse duration protocol could potentially under-
estimate the IC50 values for some compounds, the strategy
that we have outlined here is based on correlation analyses
using these IC50 values; one could use longer pulse protocols,
provided correlation analyses are done and appropriate
adjustments are made to the evaluation strategy outlined
in Figure 5.
Specific elements of the guinea-pig protocol contributing
to the precision of the data include anaesthesia, ventilation
and a single-dose testing regimen. Inactin provides a rapid
induction, whereas urethane provides a uniform mainte-
nance of anaesthesia with minimal inhibition of the
autonomic system. Both anaesthetics lack any reported
effects on QTc, unlike other anaesthetic agents, such as
pentabarbitone, isoflurane and halothane. Artificial
ventilation ensures that cardiovascular effects secondary to
respiratory depression are minimized. We avoided multiple
dosing to the same animal (Hauser et al., 2005) and instead
used a single dose per animal to enable accurate assessments
of plasma concentrations of drug. We also limited the
volume infused (1mL) to minimize effects on haemo-
dynamic function and reduce the experimental duration of
the preparation to minimize its deterioration over time.
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Figure 4 Summary of QTc (heart rate corrected QT interval of the ECG) expressed as differences from vehicle. The y axis shows the mean
difference from vehicle (of baseline-corrected QTc) for each drug and the low (L), medium (M) and high (H) doses (Table 3) that were tested in
the anaesthetized guinea-pig model. QTc values that are significantly higher than vehicle (Po0.05) are indicated by asterisks. Every drug in
groups A and B showed at least one significant increase over vehicle, but none of the drugs in group C had any significant increases over
vehicle.
In vitro hERG IC50 determined with electrophysiology
QTc evaluation in the guinea-pig model
Calculation of in vivo
Safety Margin (SMiv)
hERG/QTc Testing Strategy
Hold
IC50 > 10 µM
∆QTc < 5%
SMiv < 30
Proceed
IC50 = 1-10 µM IC50 < 1 µM
∆QTc > 5%
SMiv > 30
Figure 5 A testing strategy incorporating the hERG (human ether
a-go-go-related gene) electrophysiology and anaesthetized guinea-
pig QTc (heart rate corrected QT interval of the ECG) assays. The
solid lines represent the standard progression path, whereas the
dashed lines represent exceptions on a case-by-case basis. Com-
pounds are initially evaluated in a hERG electrophysiology assay
conducted using the defined protocol described in Methods.
Compounds with hERG IC50 values of 410mM are usually
progressed, whereas compounds with IC50 values of o1mM are
usually withheld. Compounds with hERG IC50 values between 1 and
10mM are evaluated for their potential to prolong the QTc in a
specific anaesthetized guinea-pig model (see Methods for protocol
details). If a compound is found to prolong QTc in this model, an in
vivo safety margin (SMiv) is calculated by dividing the peak drug
concentration obtained from an anaesthetized guinea-pig study
(where the QTc increased by more than 5%) by the peak drug
concentration obtained during an efficacy study in an appropriate
animal model. If the SMiv is greater than 30, the compound is
further progressed; if the SMiv is less than 30, the compound is put
on ‘hold’, and research continues for an alternative clinical
candidate.
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British Journal of Pharmacology (2008) 154 1446–1456Despite its many advantages, one limitation of this guinea-
pig model is the requirement that the test compound be
soluble in a vehicle suitable for slow intravenous infusion.
The present study showed that our anaesthetized guinea-
pig model mimics drug-induced QTc prolongation in
humans. An important finding of our study was that a 5%
increase in QTc (over vehicle) is a useful cutoff value for
detecting significant QTc prolongation in this model. Group
C drugs, including amoxicillin, aspirin, captopril, proprano-
lol and verapamil, which are not associated with QT
prolongation in humans, did not reach the 5% increase of
QTc in the guinea-pig model, whereas every compound in
groups A and B exceeded the 5% risk signal for one or more
doses. These observations would indicate that the cutoff
value of 5% is a reasonable threshold for detecting
compounds with potential clinical QT risk. Furthermore,
our guinea-pig model elicited dose-dependent QTc prolonga-
tion with moxifloxacin, a commonly utilized positive
control in ‘Thorough QT Studies’ for detecting QT effects
of investigational drugs in clinical trials. A single 400mg
dose of moxifloxacin, which prolongs the QT interval in
humans with a plasma Cmax of approximately 7mM, was
mimicked by our guinea-pig model (Figure 3a and Table 3).
A poor understanding of the mechanisms underlying TdP
has always imposed limitations for predicting its risk
through evaluation of QT interval. Our experience suggests
that excessive QT prolongation in conjunction with drug
exposure is likely to be associated with TdP. Pro-arrhythmic
paradigms, such as isolated canine Purkinje fibres (Champeroux
et al., 2005), and rabbit heart (Hondeghem and Hoffmann,
2003; Liu et al., 2006) or other electrocardiographic measures
such as transmural dispersion have been claimed to be better
surrogate markers for TdP; the latter has not been extensively
validated in the clinic (Antzelevitch, 2001). Hondeghem and
colleagues proposed triangulation, reverse use dependency,
electrical instability of the action potential, and dispersion as
a potential specific TdP predictor (Shah and Hondeghem,
2005). A major limitation of all in vitro preparations is the
absence of any plasma drug exposure data for estimating in
vivo safety ratios. To date, measurement of the QT interval in
the clinic remains the only acceptable indicator of TdP
liability. Moreover, the requirement of the Thorough QT
Study in humans for many drugs is a reflection of the
inefficiency of preclinical guidelines to predict QT prolonga-
tion in humans, even though studies of 19 compounds
showed a satisfactory correlation between TQT and preclini-
cal results (Cavero, 2008). Using these analyses of hERG
inhibitory potency in conjunction with drug exposures and
QTc interval changes in the anaesthetized guinea-pig model,
we have developed a strategy, schematically depicted in
Figure 5, for selecting drug candidates during early drug
development with a reduced risk of human QT prolongation.
In our experience, compounds with hERG IC50 values of less
than 1mM usually prolong QTc in the anaesthetized guinea-
pig. Such compounds are usually not progressed unless they
are potent at the primary target and efficacious in an animal
model at low plasma exposures. Compounds with hERG IC50
values above 10mM usually do not prolong QTc in anaes-
thetized guinea-pigs. However, certain classes of compounds,
such as antibiotics, can achieve high plasma levels and
prolong QTc, although they might be weak hERG inhibitors.
Compounds with hERG IC50 values between 1 and 10mM are
evaluated in anaesthetized guinea-pigs. If a compound is
found to prolong QTc in this model, then an in vivo SM
(SMiv) is calculated for decision-making, as elaborated in
Figure 5. Although hERG inhibition may be useful for
predicting QTc prolongation, it cannot be considered in
isolation. Verapamil is not associated with QT prolongation
and TdP in humans, but inhibits hERG with an IC50 of
0.94mM (Figure 1 and Table 2). However, as verapamil blocks
cardiac calcium channels—its primary mechanism, leading
to QT shortening—as well as hERG, the net effect on cardiac
action potential duration is not markedly changed. In
agreement with clinical observations, verapamil did not
prolong the QT interval in our guinea-pig model. These
findings underscore the importance of considering other
cardiac ion channels for evaluation of drug safety (Fermini
and Fossa, 2003; Bass et al., 2005; Salama and London, 2007).
At the GlaxoSmithKline Center for Excellence in Drug
Discovery (Research Triangle Park, NC, USA) we have used
this strategy to successfully evaluate and select a variety of
drug candidates for human clinical trials over the past 10
years. Subsequent data have repeatedly confirmed our predic-
tions of risk for QTc prolongation of these drugs in humans.
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